Key facts
- This page summarizes Martha E. Manning's Form 4 filing for MARINUS PHARMACEUTICALS, INC..
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Aug 2023, 21:05.
Martha E. Manning - 07 Aug 2023 Form 4 Insider Report for MARINUS PHARMACEUTICALS, INC.
- Reporting relationship
- SVP, GEN. COUNSEL & CORP. SEC.
- Issuer ticker
- N/A
- Reported as of
- 07 Aug 2023
- Net transaction value
- -$20,790
- SEC form
- 4
- Accepted by SEC
- 08 Aug 2023, 21:05:12 UTC
- Prior SEC filing
- 30 Jan 2023
- Next SEC filing
- 19 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Debra A. Mohollen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Martha E. Manning filed Form 4 for MARINUS PHARMACEUTICALS, INC. on 08 Aug 2023.
Change
- Previous filing in this sequence was filed on 30 Jan 2023.
- Current net transaction value: -$20,790.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNS
transaction
Common Stock
Sale
- Transaction value
- $20,692
- Shares
- -2,169
- Change %
- -6.2%
- Price
- $9.54
- Shares after
- 33,036
- Date
- 07 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
MRNS
transaction
Common Stock
Sale
- Transaction value
- $98.23
- Shares
- -11
- Change %
- -0.03%
- Price
- $8.93
- Shares after
- 33,025
- Date
- 08 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units.
Footnote F2
The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.34 to $9.84, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
Footnote F3
The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $8.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.